{"id":206775,"name":"DENDREON PHARMACEUTICALS, LLC","slug":"dendreon-pharmaceuticals-llc","state":"CA","country":"United States of America","description":"","totalSpending":2632413,"filings":30,"yearlySpending":[{"year":2019,"income":333750},{"year":2020,"income":480000},{"year":2021,"income":495500},{"year":2022,"income":457269},{"year":2023,"income":416212},{"year":2024,"income":271098},{"year":2025,"income":178584}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"},{"code":"VET","display":"Veterans"},{"code":"MED","display":"Medical/Disease Research/Clinical Labs"}],"firms":["DENDREON PHARMACEUTICALS, LLC"],"lobbyists":["ANDREW SAELENS"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Medicare Part B Payment Reform","Medicare Part B payment reform\n\nClinical pathway for prostate cancer at the VA","Medicare Part B payment reform\n\nClinical pathway for prostate cancer at the VA","Access to prostate cancer immunotherapy at the Veterans Health Administration","Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019."]}